Changes in contractile properties of muscles receiving repeat injections of botulinum toxin (Botox)

Journal of Biomechanics

Volumn 44, Issue 1, 2011, Pages 39-44

  Fortuna, Rafael ^a   Aurélio Vaz, Marco ^b   Rehan Youssef, Aliaa ^a   Longino, David ^a   Herzog, Walter ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Botulinum toxin type A; Knee; Muscle paralysis; Muscle weakness; Rabbit

Indexed keywords

ADVERSE EFFECT; BOTULINUM TOXIN TYPE-A; BOTULINUM TOXINS; KNEE; KNEE EXTENSOR; MUSCLE ATROPHY; MUSCLE MASS; MUSCLE WEAKNESS; NEUROMUSCULAR DISORDERS; NEW ZEALAND; RABBIT; RECTUS FEMORIS; THERAPEUTIC TOOLS; US FOOD AND DRUG ADMINISTRATION; VASTUS MEDIALIS;

ANIMALS; TOXIC MATERIALS;

MUSCLE;

BOTULINUM TOXIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXTENSOR MUSCLE; FEMALE; HISTOPATHOLOGY; MUSCLE ATROPHY; MUSCLE CONTRACTILITY; MUSCLE MASS; MUSCLE STRENGTH; MUSCLE WEAKNESS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RABBIT; RECTUS FEMORIS MUSCLE; TORQUE; VASTUS LATERALIS MUSCLE; VASTUS MEDIALIS MUSCLE;

ANIMALS; BIOMECHANICS; BOTULINUM TOXINS, TYPE A; FEMALE; HINDLIMB; MUSCLE CONTRACTION; MUSCLE STRENGTH; MUSCULAR ATROPHY; QUADRICEPS MUSCLE; RABBITS; TIME FACTORS;

EID: 78650010349     PISSN: 00219290     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiomech.2010.08.020     Document Type: Article

References (33)

1. Antonucci F., Rossi C., Gianfranceschi L., Rosseto O., Caleo M. Long-distance retrograde effects of botulinum neurotoxin A. The Journal of Neuroscience 2008, 28(14):3689-3696.
2. Ansved T., Odergren T., Borg K. Muscle fiber atrophy in leg muscles after botulinum toxin type A treatment of cervical dystonia. Neurology 1997, 48:1440-1442.
3. Brin M.F. Botulinum toxin: chemistry, pharmacology, toxicity and immunology. Muscle and Nerve Supplement 1997, 6:146-168.
4. Borodic G.E., Joseph M., Fay L., Cozzolino D., Ferrante R.J. Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head and Neck 1990, 12(5):392-399.
5. Borodic G.E., Pearce L.B., Smith K., Joseph M. Botulinum A toxin for spasmodic torticollis: multiple vs single injection points per muscle. Head and Neck 1992, 14:33-37.
6. Cichon J.V., McCaffrey T.V., Litchy W.J., Knops J.L. The effect of botulinum toxin type. A injection on compound muscle action potential in an in vivo rat model. 1995, 105:144-148.
7. Cote T.R., Mohan A.K., Polder J.A., Walton M.K., Braun M.M. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. Journal American Academic of Dermatology 2005, 53:4017-4415.
8. Delgado M.R., Hirtz D., Aisen M., et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review). American Academy of Neurology 2010, 74:336-343.
9. Dodd S.L., Selsby J., Payne A., Judge A., Dott C. Botulinum neurotoxin type A causes shifts in myosin heavy chain composition in muscle. Toxicon 2005, 46:196-203.
10. Dutton J.J. Botulinum-A toxin in the treatment of craniocervical muscle spasms: short-and long-term, local and systemic effects. Survey of Ophthalmology 1996, 41:51-65.
11. Garner C.G., Straube A., Witt T.N., Gasser T., Oertel W.H. Time course of distant effects of local injections of botulinum toxin. Movement Disorders 1993, 8:33-37.
12. Graham H.K., Aoki K.R., Mo I.A., et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait and Posture 2000, 11:67-79.
13. Girlanda P., Vita G., Nicolosi C., Milone S., Messina C. Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. Journal of Neurology, Neurosurgery and Psychiatry 1992, 844-845.
14. Heinen F., Desloovere K., Schroeder A.S., et al. The updated European Consensus 2009 on the use of botulinum toxin for children with cerebral palsy. Journal of the European Paediatric Neurology Society 2009, 14:54-66.
15. Herzog W., Leonard T.R. Depression of cat soleus forces following isokinetic shortening. Journal of Biomechanics 1997, 30(9):865-872.
16. Herzog W., Leonard T.R. Force enhancement following stretching of skeletal muscle: a new mechanism. Journal of Experimental Biology 2002, 205:1275-1283.
17. Herzog W., Longino D. The role of muscle in joint degeneration and osteoarthritis. Journal of Biomechanics 2007, 40:S54-S63.
18. Hamalainem N., Pette D. The histochemical profiles of fast fiber types IIB, IID, and IIA in skeletal muscles of mouse, rat, and rabbit. The Journal of Histochemistry and Cytochemistry 1993, 41(5):733-743.
19. Inagi K., Connor N.P., Schultz E., Ford C.N., Cook C.H., Heisey D.N. Muscle fiber-type changes induced by botulinum toxin injection in the rat larynx. Otolaryngology-Head and Neck Surgery 1999, 120:876-883.
20. Koman A.L., Mooney J.F., Smith B., et al. Management of cerebral palsy with botulinum-A toxin: preliminary investigation. Journal of Pediatric Orthopaedics 1993, 13:489-495.
21. Lange D.L., Mitchell F.B., Warner C.L., Fahn S., Lovelace R.E. Distant effects of local injection of botulinum toxin. Muscle & Nerve 1987, 10:552-555.
22. Lange D.L., Rubin M., Greene P.E., Kang U.J., Moskowitz C.B., Brin M.F., et al. Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle and Nerve 1991, 14:672-675.
23. Lange F., Weerden T.W., Hoeven J.H. Age-related botulinum toxin effects on muscle fiber conduction velocity in non-injected muscles. Clinical Neurophysiology 2007, 118:2398-2403.
24. Longino D., Butterfield T., Herzog W. Frequency and length dependent effects of botulinum toxin-induced muscle weakness. Journal of Biomechanics 2005, 25:1329-1335.
25. Longino D., Frank C., Leonard T.R., Vaz M.A., Herzog W. Proposed model of botulinum toxin-induced muscle weakness in the rabbit. Journal of Orthopedic Research 2005, 23:1411-1418.
26. Longino D., Frank C., Herzog W. Acute botulinum toxin-induced muscle weakness in the anterior cruciate ligament-deficient rabbit. Journal of Orthopaedic Research 2005, 23:1404-1410.
27. Morton R.E., Hankinson J., Nicholson J. Botulinum toxin for cerebral palsy; where are we now?. Archives of Disease in Childhood 2004, 89:1133-1137.
28. Rab M., Neumayer C.H., Koller R., et al. Histomorphology of rabbit thigh muscles: estabilishment of standard control values. Journal of Anatomy 2000, 196:203-209.
29. Rehan Youssef A., Longino D., Seerattan R., Leonard T., Herzog W. Muscle weakness causes joint degeneration in rabbits. Osteoarthritis and cartilage 2009, 17:1228-1235.
30. Russman B.S., Tilton A., Gormley M.E. Cerebral palsy: a rational approach to a treatment protocol, and the role of botulinum toxin in treatment. Muscle and Nerve 1997, (Suppl. 6):S181-S193.
31. Shaari C.M., George E., Wu B., Biller H.F., Sanders I. Quantifying the spread of botulinum toxin through muscle fascia. Laryngoscope 1991, 101:960-964.
32. Wissel J., Ward A.B., Erztgaard P., et al. European Consensus table on the use of botulinum toxin type A in adult spasticity. Journal of rehabilitation Medicine 2009, 2009(41):13-25.
33. Yaraskavitch M., Leonard T., Herzog W. Botox produces functional weakness in non-injected muscles adjacent to the target muscle. Journal of Biomechanics 2008, 41:902-987.